CN102949708B - 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 - Google Patents
人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 Download PDFInfo
- Publication number
- CN102949708B CN102949708B CN201210442685.6A CN201210442685A CN102949708B CN 102949708 B CN102949708 B CN 102949708B CN 201210442685 A CN201210442685 A CN 201210442685A CN 102949708 B CN102949708 B CN 102949708B
- Authority
- CN
- China
- Prior art keywords
- sdr5
- protein
- myocardial infarction
- fusion protein
- antibody fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210442685.6A CN102949708B (zh) | 2012-11-08 | 2012-11-08 | 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 |
PCT/CN2012/087458 WO2014071670A1 (zh) | 2012-11-08 | 2012-12-26 | 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210442685.6A CN102949708B (zh) | 2012-11-08 | 2012-11-08 | 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102949708A CN102949708A (zh) | 2013-03-06 |
CN102949708B true CN102949708B (zh) | 2014-05-07 |
Family
ID=47759468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210442685.6A Active CN102949708B (zh) | 2012-11-08 | 2012-11-08 | 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102949708B (zh) |
WO (1) | WO2014071670A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
CN105688189A (zh) * | 2016-01-21 | 2016-06-22 | 河南大学 | 人sDR5-Fc抗体融合蛋白作为肾损伤治疗药物的应用 |
US11220533B2 (en) | 2016-01-29 | 2022-01-11 | Shenzhen Zhongke Amshenn Pharmaceutical Co., Ltd. | Human sDR5-fc recombinant fusion protein and application thereof |
CN108997503B (zh) * | 2017-06-06 | 2021-07-23 | 深圳市中科艾深医药有限公司 | 人sDR5-Fc重组融合蛋白及其作为制备治疗生殖系统炎症的药物中的应用 |
CN112294945A (zh) * | 2019-08-01 | 2021-02-02 | 深圳市中科艾深医药有限公司 | 人sDR5-Fc重组融合蛋白在制备防治心肌梗死、缺血再灌注损伤的药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080248046A1 (en) * | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
CN100398149C (zh) * | 2006-06-09 | 2008-07-02 | 山东大学 | 人sDR5蛋白在制备治疗乙型病毒性肝炎药物中的应用 |
-
2012
- 2012-11-08 CN CN201210442685.6A patent/CN102949708B/zh active Active
- 2012-12-26 WO PCT/CN2012/087458 patent/WO2014071670A1/zh active Application Filing
Non-Patent Citations (6)
Title |
---|
HBV致肝细胞凋亡及肝癌形成的分子机制研究;刘玉刚;《中国博士学位论文全文数据库》;20071231(第3期);66、72、77 * |
于少娟.急性心肌梗死早期血清sTRAIL与IL_10的变化及相关性研究.《中国优秀硕士学位论文全文数据库》.2007,(第2期),摘要,第15页. |
刘玉刚.HBV致肝细胞凋亡及肝癌形成的分子机制研究.《中国博士学位论文全文数据库》.2007,(第3期),66、72、77. |
急性心肌梗死早期血清sTRAIL与IL_10的变化及相关性研究;于少娟;《中国优秀硕士学位论文全文数据库》;20071231(第2期);摘要,第15页 * |
李志刚.死亡受体及其配体与心肌细胞凋亡.《中国组织化学与细胞化学杂志》.2002,第11卷(第3期),333-334. |
死亡受体及其配体与心肌细胞凋亡;李志刚;《中国组织化学与细胞化学杂志》;20020930;第11卷(第3期);333-334 * |
Also Published As
Publication number | Publication date |
---|---|
CN102949708A (zh) | 2013-03-06 |
WO2014071670A1 (zh) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102949708B (zh) | 人sDR5蛋白或sDR5-Fc抗体融合蛋白作为心肌梗死治疗药物的应用 | |
JP5048673B2 (ja) | 血栓性疾患の予防あるいは治療を行う一種の抽出物 | |
US20210346281A1 (en) | Multi-component injection | |
CN105693867B (zh) | 人sDR5-Fc重组融合蛋白及其新应用 | |
JPH0418028A (ja) | 肝硬変治療剤 | |
CN101611061B (zh) | 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物 | |
WO2021244010A1 (zh) | 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用 | |
CN110724203A (zh) | 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用 | |
De Azevedo et al. | Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation | |
WO2023065684A1 (zh) | 辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用 | |
EP2799445B1 (en) | Integrin blocker polypeptide for use in the treatment of rheumatoid arthrits | |
Konturek | Comparison of pancreatic responses to natural and synthetic secretins in conscious cats | |
EP4275703A1 (en) | Use of pd1 inhibitor in preparation of cardiac fibroblast transdifferentiation inhibitor | |
CN103520193A (zh) | 一种药物组合物及其制备方法 | |
CN103405501B (zh) | 三味活血化瘀胶囊的制取方法 | |
WO1998024467A1 (fr) | Medicaments contre l'hepatite fulminante | |
CN110169963A (zh) | 对香豆酸作为制备用于舒张气道平滑肌的药物的应用 | |
CN111892660A (zh) | 一种构建长qt综合征动物模型的多肽 | |
CN111569046A (zh) | 多肽在制备治疗胰腺炎药物中的用途及含有其的药物 | |
CN111514209A (zh) | 一种中药组合物在制备预防和/或治疗心肌缺血再灌注损伤的药物中的应用 | |
CN114652717B (zh) | 盐酸萘甲唑啉的药物用途 | |
CN105535890B (zh) | 一种治疗心血管疾病的药物组合物及其制备方法 | |
CN102988399A (zh) | 一种药物组合物及用途和制剂 | |
CN101671388B (zh) | 血脑屏障穿透性促红细胞生成素及其应用 | |
CN114642668B (zh) | 拉坦前列素的药物新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ma Yuanfang Inventor after: Wang Yaohui Inventor after: Wang Mingli Inventor after: Zhang Jun Inventor after: Liu Guangchao Inventor after: Li Shulian Inventor after: Liu Fengtao Inventor after: Hu Yanzhong Inventor before: Ma Yuanfang Inventor before: Chen Youhai Inventor before: Wang Mingli Inventor before: Wang Yaohui Inventor before: Zhang Jun Inventor before: Liu Guangchao Inventor before: Li Shulian Inventor before: Liu Fengtao Inventor before: Hu Yanzhong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MA YUANFANG CHEN YOUHAI WANG MINGLI WANG YAOHUI ZHANG JUN LIU GUANGCHAO LI SHULIAN LIU FENGTAO HU YANZHONG TO: MA YUANFANG WANG YAOHUI WANG MINGLI ZHANG JUN LIU GUANGCHAO LI SHULIAN LIU FENGTAO HU YANZHONG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200519 Address after: 215000 station R2006, unit 201, B6 floor, phase I project, biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province (cluster registration) Patentee after: Suzhou Yongxin Biotechnology Co., Ltd Address before: 475001 Henan province city Minglun Street No. 85 Patentee before: Henan University |
|
TR01 | Transfer of patent right |